Sugi Predict

Sugi Predict / Compounds / SCHEMBL128077

SCHEMBL128077

SCHEMBL128077

CCOC(=O)C=C1c2ccccc2-c2ccccc21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ P2RY12 Q9H244 1/20 0.53
▸ MAPT P10636 5/20 0.50
▸ LMNA P02545 2/20 0.50
▸ MDM2 Q00987 1/20 0.50
▸ TSHR P16473 1/20 0.46
▸ KDM4E B2RXH2 1/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ CASP1 P29466 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ CTDSP1 Q9GZU7 3/20 0.43
▸ ALDH1A1 P00352 2/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ CA12 O43570 1/20 0.41
▸ CA1 P00915 1/20 0.41
▸ CA2 P00918 1/20 0.41
▸ CA7 P43166 1/20 0.41
▸ CA9 Q16790 1/20 0.41
▸ CA14 Q9ULX7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14422825 0.88 P2RY12 (0.45) P2RY12MAPTLMNAMDM2KDM4E
SCHEMBL8206612 0.86 LMNA (0.46) P2RY12MAPTLMNAMDM2TSHR
SCHEMBL17305924 0.85 GABRP (0.49) P2RY12MAPTLMNAMDM2TSHR
SCHEMBL4305031 0.85 SMN1; SMN2 (0.52) P2RY12MAPTLMNAMDM2TSHR
SCHEMBL17307864 0.84 MAPT (0.43) P2RY12MAPTLMNAMDM2TSHR
SCHEMBL11182296 0.82 P2RY12 (0.44) P2RY12MAPTLMNAMDM2KDM4E
SCHEMBL11182306 0.82 P2RY12 (0.44) P2RY12MAPTLMNAMDM2KDM4E
SCHEMBL10203758 0.80 PPARG (0.53) LMNAMEN1KMT2AALDH1A1
SCHEMBL7871493 0.79 MAPT (0.43) P2RY12MAPTLMNAMDM2TSHR
SCHEMBL24704037 0.79 CDC25A (0.47) P2RY12MAPTLMNATSHRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109337342-A A kind of electronic material composition of balancing performance 安徽丹凤电子材料股份有限公司 2019-02-15 — — CN claimed
CN-108587074-A High-melting-point electronic material 太仓双赢电子电气成套设备有限公司 2018-09-28 — — CN claimed
CN-108384172-A A kind of dystectic electronic material and preparation method thereof 合肥励仙电力工程有限公司 2018-08-10 — — CN claimed
CN-105670286-A Alkali-corrosion-resistant organic magnetic material and preparation method thereof 苏州科茂电子材料科技有限公司 2016-06-15 — — CN claimed
CN-105647090-A High-melting-point heat-conducting electronic material and preparation method thereof 苏州科茂电子材料科技有限公司 2016-06-08 — — CN claimed
WO-2022255228-A1 COMPOSITION, CURED PRODUCT OR COMPACT, OPTICAL MEMBER, AND LENS 富士フイルム株式会社 2022-12-08 — — WO disclosed
CN-109337342-A A kind of electronic material composition of balancing performance 安徽丹凤电子材料股份有限公司 2019-02-15 — — CN disclosed
CN-109337342-A A kind of electronic material composition of balancing performance 安徽丹凤电子材料股份有限公司 2019-02-15 — — CN disclosed
CN-108587074-A High-melting-point electronic material 太仓双赢电子电气成套设备有限公司 2018-09-28 — — CN disclosed
CN-108384172-A A kind of dystectic electronic material and preparation method thereof 合肥励仙电力工程有限公司 2018-08-10 — — CN disclosed
CN-105670286-A Alkali-corrosion-resistant organic magnetic material and preparation method thereof 苏州科茂电子材料科技有限公司 2016-06-15 — — CN disclosed
CN-105647090-A High-melting-point heat-conducting electronic material and preparation method thereof 苏州科茂电子材料科技有限公司 2016-06-08 — — CN disclosed
EP-1965805-A1 UREA DERIVATIVES USEFUL AS CALCIUM RECEPTOR MODULATORS Proskelia SAS (FR) 2008-09-10 — — EP disclosed
EP-1874765-A2 UREA DERIVATIVES METHODS FOR THEIR MANUFACTURE AND USES THEREOF Proskelia SAS (FR) 2008-01-09 — — EP disclosed
US-20070179134-A1 Urea derivatives, processes for their preparation, their use as medicaments, and pharmaceutical compositions containing them PROSKELIA SAS. (FR) 2007-08-02 — — US disclosed
US-20070179134-A1 Urea derivatives, processes for their preparation, their use as medicaments, and pharmaceutical compositions containing them PROSKELIA SAS. (FR) 2007-08-02 — — US disclosed
US-20070179134-A1 Urea derivatives, processes for their preparation, their use as medicaments, and pharmaceutical compositions containing them PROSKELIA SAS. (FR) 2007-08-02 — — US disclosed
WO-2007060026-A1 UREA DERIVATIVES USEFUL AS CALCIUM RECEPTOR MODULATORS GALAPAGOS SAS (FR) 2007-05-31 — — WO disclosed
WO-2007060026-A1 UREA DERIVATIVES USEFUL AS CALCIUM RECEPTOR MODULATORS GALAPAGOS SAS (FR) 2007-05-31 — — WO disclosed
WO-2006117211-A2 UREA DERIVATIVES METHODS FOR THEIR MANUFACTURE AND USES THEREOF PROSKELIA SAS (FR) 2006-11-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179134-A1 Urea derivatives, processes for their preparation, their use as medicaments, and pharmaceutical compositions containing them UTS2R, CACNA1A, CACNA1E P2RY12 790/4885MAPT 1884/4885LMNA 1829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.